Developing a new drug to help people with stimulant use disorders
Official title: Investigation of a Novel PDE4B Inhibitor for Stimulant Use Disorder
Funded at Fannin Partners, LLC · NIH-10908017 · Data updated 2026-11-12
This study is testing a new medication called 11h to help people struggling with stimulant use disorders, like cocaine addiction, and it aims to do this with fewer side effects than current treatments.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fannin Partners, LLC NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $320,000 |
| NIH project number | 1R43DA060646-01 |
| Project ID | NIH-10908017 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with stimulant use disorders, particularly those who have not responded well to existing treatments.
✕Less likely to help
Patients who do not have stimulant use disorders or those who are not seeking treatment for substance use issues may not benefit from this research.
What this research studies
This research focuses on creating a new medication, known as 11h, aimed at treating stimulant use disorders (StUD), which have become increasingly common. The approach involves selectively inhibiting an inflammatory pathway in the brain, which may lead to fewer side effects compared to existing treatments. The drug has shown promising results in animal models, demonstrating effectiveness against substances like cocaine and exhibiting good safety and absorption characteristics. The goal is to advance this drug through early testing phases to assess its efficacy and safety in humans.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for individuals struggling with stimulant use disorders.
How similar studies have gone: Previous research has shown promise in developing targeted treatments for substance use disorders, but this specific approach using PDE4B inhibition is relatively novel.
Where this research is happening
-
Fannin Partners, LLC
Houston, United States Active
Researchers
- Principal investigator: Varadhachary, Atul — Fannin Partners, LLC
- Study coordinator: Varadhachary, Atul
Related research
Other NIH-funded projects on the same topics.
-
New IL-7 receptor antibody treatment for relapsed T‑cell leukemia
A new antibody that targets the IL‑7 receptor is being tested as a treatment for children and adults whose T‑cell acute lymphoblastic leukemia has come back.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.